Skip to content

Efficacy and Safety of Light Compression System in the Local Treatment of Mixed Leg Ulcers (PROMETHEE Clinical Investigation)

Evaluation of the Efficacy and Safety of Light Compression System Versus Tubular Bandage in the Local Treatment of Mixed Leg Ulcers: a Prospective Open-label RCT

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06899919
Acronym
PROMETHEE
Enrollment
210
Registered
2025-03-28
Start date
2025-03-29
Completion date
2027-09-30
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leg Ulcers

Keywords

Mixed leg ulcers, Quality of life questionnaire, light compression system

Brief summary

Evaluation of the efficacy (wound epithelialization and time to closure) and safety (emergence and nature of adverse event) of a lite compression system versus a tubular bandage in the local treatment of mixed leg ulcers: prospective multicenter, randomized controlled, open-label french clinical study

Detailed description

This is a prospective, randomized, controlled, open-label, multicenter clinical trial conducted in patients with a mixed (non-ischemic) leg ulcer of stage C6 / C6r of the CEAP classification. This study is carried out in around 50 French investigational centers. A total of 210 patients meeting the eligibility criteria will be included. The patients will be followed for 16 weeks and a total of 6 clinical evaluations will be carried out by the investigating centers. A planimetric survey of the studied leg ulcers is carried out during the initial assessment of the wound (Day 0) and at each assessment provided for in the protocol (Week 2, Week 4, Week 8 and Week 12). A QoL is carried out at D0 and end of the study for each patient included in the protocol.

Interventions

DEVICETreatment with light compression systeme during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)

Treatment with light compression system during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)

DEVICELight compression system of the mixed leg ulcer stage C6 / C6r of the CEAP classification

Etiological treatment of mixed leg ulcer stage C6 / C6r of the CEAP classification

Sponsors

Laboratoires URGO
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

randomization 2:1 (light compression system vs tubular bandage)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient (≥ 18 years old), having given free, informed and written consent * Patient affiliated to a social security scheme * Patient agreeing to wear the study compression system daily * Patient with an ankle circumference between 18 and 25 cm * Target wound: stage C6 / C6r mixed leg ulcer of the CEAP classification with a 0.6≤ ABPI≤0.8 and TABP≥ 50 mm Hg and arterial echo Doppler confirming the mixed nature of the leg ulcer * Target wound with an area between 2 and 20 cm2 * Target wound with age of ≤18 months Criteria exclusion: * Patient with a systemic infection not controlled by appropriate antibiotic therapy * Patient having presented in the 3 months preceding his inclusion, a deep vein thrombosis * Severe arterial pathology, including an Ankle Blood Pressure Index (ABPI) less than 3 months old \<0.6 * Patient bedridden or spending less than an hour per day standing * Clinically infected target wound * Cancerized target wound

Design outcomes

Primary

MeasureTime frameDescription
Complete closure of the Venous Leg Ulcer (VLU)16-week treament periodDescription: Complete closure of the leg ulcer is defined by 100% re-epithelialization of the mixed Leg Ulcer (MLU)

Secondary

MeasureTime frameDescription
Time to complete closure of the Venous Leg Ulcer (VLU)16-week treament periodDescription: Time to complete closure of the Mixed Leg Ulcer (MLU) is defined as the time from inclusion to the date of complete closure
Safety analysis16-week treament periodNature and number of adverse event related to the use of the studied light compression system and tubular bandage (serious/ non-serious and emergent)

Countries

France

Contacts

Primary ContactAnne AnS SAUVADET, Dr, PhD
a.sauvadet@fr.urgo.com+33 6 71 19 78 91
Backup ContactOlivier OlT TACCA, Dr, PhD
o.tacca@fr.urgo+33 3 80 44 74 22

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026